Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Angel Guzman-Perez

Showing results (11-20 of 45) with videos related to

Pageof 5
Sort By:
ACS Medicinal Chemistry Letters|June 6, 2014
Structure-based design of 2-aminopyridine oxazolidinones as potent and selective tankyrase inhibitorsHongbing Huang, Angel Guzman-Perez, Lisa Acquaviva, et al.
Journal of Chemical Information and Modeling|December 10, 2019
Correction to Analyzing Learned Molecular Representations for Property PredictionKevin Yang, Kyle Swanson, Wengong Jin, et al.
Journal of Chemical Information and Modeling|July 31, 2019
Analyzing Learned Molecular Representations for Property PredictionKevin Yang, Kyle Swanson, Wengong Jin, et al.
Bioorganic & Medicinal Chemistry Letters|September 13, 2011
Design and synthesis of potent, orally-active DGAT-1 inhibitors containing a dioxino[2,3-d]pyrimidine coreRobert L Dow, Melissa Andrews, Gary E Aspnes, et al.
Bioorganic & Medicinal Chemistry Letters|January 25, 2021
Discovery of 6-Oxo-4-phenyl-hexanoic acid derivatives as RORγt inverse agonists showing favorable ADME profileRyota Nakajima, Hiroyuki Oono, Keiko Kumazawa, et al.
Bioorganic & Medicinal Chemistry|July 23, 2013
Defining the key pharmacophore elements of PF-04620110: discovery of a potent, orally-active, neutral DGAT-1 inhibitorRobert L Dow, Melissa P Andrews, Jian-Cheng Li, et al.
Bioorganic & Medicinal Chemistry Letters|May 12, 2009
Sulfoximine-substituted trifluoromethylpyrimidine analogs as inhibitors of proline-rich tyrosine kinase 2 (PYK2) show reduced hERG activityDaniel P Walker, Michael P Zawistoski, Molly A McGlynn, et al.
Bioorganic & Medicinal Chemistry Letters|May 14, 2009
Pyridones as glucokinase activators: identification of a unique metabolic liability of the 4-sulfonyl-2-pyridone heterocycleJeffrey A Pfefferkorn, Jihong Lou, Martha L Minich, et al.
Cancer Discovery|August 25, 2023
STX-478, a Mutant-Selective, Allosteric PI3Kα Inhibitor Spares Metabolic Dysfunction and Improves Therapeutic Response in PI3Kα-Mutant XenograftsLeonard Buckbinder, David J St Jean, Trang Tieu, et al.
Bioorganic & Medicinal Chemistry Letters|July 8, 2017
Discovery of a biarylamide series of potent, state-dependent Na<sub>V</sub>1.7 inhibitorsLaurie B Schenkel, Erin F DiMauro, Hanh N Nguyen, et al.
Pageof 5

Showing results (11-20 of 45) with videos related to

Sort By:
Pageof 5
ACS Medicinal Chemistry Letters|June 6, 2014
Structure-based design of 2-aminopyridine oxazolidinones as potent and selective tankyrase inhibitorsHongbing Huang, Angel Guzman-Perez, Lisa Acquaviva, et al.
Journal of Chemical Information and Modeling|December 10, 2019
Correction to Analyzing Learned Molecular Representations for Property PredictionKevin Yang, Kyle Swanson, Wengong Jin, et al.
Journal of Chemical Information and Modeling|July 31, 2019
Analyzing Learned Molecular Representations for Property PredictionKevin Yang, Kyle Swanson, Wengong Jin, et al.
Bioorganic & Medicinal Chemistry Letters|September 13, 2011
Design and synthesis of potent, orally-active DGAT-1 inhibitors containing a dioxino[2,3-d]pyrimidine coreRobert L Dow, Melissa Andrews, Gary E Aspnes, et al.
Bioorganic & Medicinal Chemistry Letters|January 25, 2021
Discovery of 6-Oxo-4-phenyl-hexanoic acid derivatives as RORγt inverse agonists showing favorable ADME profileRyota Nakajima, Hiroyuki Oono, Keiko Kumazawa, et al.
Bioorganic & Medicinal Chemistry|July 23, 2013
Defining the key pharmacophore elements of PF-04620110: discovery of a potent, orally-active, neutral DGAT-1 inhibitorRobert L Dow, Melissa P Andrews, Jian-Cheng Li, et al.
Bioorganic & Medicinal Chemistry Letters|May 12, 2009
Sulfoximine-substituted trifluoromethylpyrimidine analogs as inhibitors of proline-rich tyrosine kinase 2 (PYK2) show reduced hERG activityDaniel P Walker, Michael P Zawistoski, Molly A McGlynn, et al.
Bioorganic & Medicinal Chemistry Letters|May 14, 2009
Pyridones as glucokinase activators: identification of a unique metabolic liability of the 4-sulfonyl-2-pyridone heterocycleJeffrey A Pfefferkorn, Jihong Lou, Martha L Minich, et al.
Cancer Discovery|August 25, 2023
STX-478, a Mutant-Selective, Allosteric PI3Kα Inhibitor Spares Metabolic Dysfunction and Improves Therapeutic Response in PI3Kα-Mutant XenograftsLeonard Buckbinder, David J St Jean, Trang Tieu, et al.
Bioorganic & Medicinal Chemistry Letters|July 8, 2017
Discovery of a biarylamide series of potent, state-dependent Na<sub>V</sub>1.7 inhibitorsLaurie B Schenkel, Erin F DiMauro, Hanh N Nguyen, et al.
Pageof 5